EUVIMEDOpdag EUVIMED
Open access

Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)

Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J Noonan, Taylor Powell, Landon Goodreau, Emily K Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R Khandelwal, Cherie-Ann O Nathan

Oncotarget · 2023-02-02 · 14 (1) · 85-95

DOI: 10.18632/oncotarget.28355 ↗

At a glance

Journal article in Oncotarget, published online on 2023-02-02. Written by Md Maksudul Alam and 10 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, LSU-Health Sciences Center, Shreveport, LA 71103, USA. Major MEDLINE topics: Everolimus, Head and Neck Neoplasms. Cited 23 times so far (Crossref); 46 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Intet abstract tilgængeligt.

Subjects

MeSH terms (MEDLINE)

EverolimusHead and Neck NeoplasmsMiceAnimalsHumansSquamous Cell Carcinoma of Head and NeckLymphangiogenesisVascular Endothelial Growth Factor AMice, NudeTumor Suppressor Protein p53TOR Serine-Threonine KinasesNeovascularization, PathologicCell Line, TumorHypoxia-Inducible Factor 1, alpha SubunitSTAT3 Transcription Factor

Author keywords

HNSCCTP53 mutantangiogenesiseverolimusmTOR

Substances

EverolimusVascular Endothelial Growth Factor ATumor Suppressor Protein p53TOR Serine-Threonine KinasesHypoxia-Inducible Factor 1, alpha SubunitTP53 protein, humanSTAT3 protein, humanSTAT3 Transcription Factor

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, LSU-Health Sciences Center, Shreveport, LA 71103, USA.
  • School of Medicine, LSU-Health Sciences Center, Shreveport, LA 71103, USA.
  • Feist-Weiller Cancer Center, LSU-Health Sciences Center, Shreveport, LA 71103, USA.

Cite

APA

Alam, M. M., Fermin, J. M., Knackstedt, M., Noonan, M. J., Powell, T., Goodreau, L., Daniel, E. K., Rong, X., Moore-Medlin, T., Khandelwal, A. R., & Nathan, C. O. (2023). Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC). Oncotarget, 14(1), 85-95. https://doi.org/10.18632/oncotarget.28355

Vancouver

Alam MM, Fermin JM, Knackstedt M, Noonan MJ, Powell T, Goodreau L, et al. Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC). Oncotarget. 2023;14(1):85-95. doi:10.18632/oncotarget.28355

BibTeX
@article{Alam2023,
  author = {Alam, Md Maksudul and Fermin, Janmaris Marin and Knackstedt, Mark and Noonan, Mackenzie J and Powell, Taylor and Goodreau, Landon and Daniel, Emily K and Rong, Xiaohua and Moore-Medlin, Tara and Khandelwal, Alok R and Nathan, Cherie-Ann O},
  title = {Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)},
  journal = {Oncotarget},
  year = {2023},
  volume = {14},
  number = {1},
  pages = {85--95},
  doi = {10.18632/oncotarget.28355}
}
Start for free →